Pattern recognition for predictive, preventive, and personalized medicine in cancer

EPMA Journal

Volumn 8, Issue 1, 2017, Pages 51-60

  Cheng, Tingting ^a   Zhan, Xianquan ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Genomics; Metabolomics; Pattern recognition; Peptidomics; Predictive preventive personalized medicine; Proteomics; Radiomics; Systems biology; Transcriptomics

Indexed keywords

LONG UNTRANSLATED RNA; MESSENGER RNA; MICRORNA; TUMOR MARKER; VOLATILE ORGANIC COMPOUND;

ALGORITHM; AUTOMATED PATTERN RECOGNITION; BIOMICS; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; COPY NUMBER VARIATION; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; ELECTRONIC NOSE; GENOMICS; GLIOMA; HUMAN; MALIGNANT NEOPLASM; MASS SPECTROMETRY; METABOLOMICS; MOLECULAR DIAGNOSIS; PEPTIDOMICS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PREVENTIVE MEDICINE; PROTEIN PROCESSING; PROTEOMICS; RADIOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS;

EID: 85016145513     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-017-0083-9     Document Type: Review

References (88)

1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546-58.
2. Hoth M. CRAC channels, calcium, and cancer in light of the driver and passenger concept. Biochim Biophys Acta. 2016;1863(6 Pt B):1408-17.
3. Liu J, Mao Y, Li Z, Zhang D, Zhang Z, Hao S, et al. Use of texture analysis based on contrast-enhanced MRI to predict treatment response to chemoradiotherapy in nasopharyngeal carcinoma. J Magn Reson Imaging. 2016;44:445-55.
4. Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, et al. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer Metastasis Rev. 2014;33:161-71.
5. Liu FF. Novel gene therapy approach for nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12:505-15.
6. Gregory TR. Synergy between sequence and size in large-scale genomics. Nat Rev Genet. 2005;6:699-708.
7. Jorde LB, Wooding SP. Genetic variation, classification and 'race'. Nat Genet. 2004;36(11 Suppl):S28-33.
8. Tan DS, Mok TS, Rebbeck TR. Cancer genomics: diversity and disparity across ethnicity and geography. J Clin Oncol. 2016;34:91-101.
9. Mroz EA, Rocco JW. The challenges of tumor genetic diversity. Cancer. 2016. doi: 10.1002/cncr.30430.
10. Müller B, Wilcke A, Boulesteix AL, Brauer J, Passarge E, Boltze J, et al. Improved prediction of complex diseases by common genetic markers: state of the art and further perspectives. Hum Genet. 2016;135:259-72.
11. Cheon S. Probability concepts and distributions for analyzing large biological data. In: Lee JK, editor. Statistical bioinformatics for biomedical and life science researchers. Hoboken: Willey; 2010. p. 7-56.
12. Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Genenames.org: the HGNC resources in. Nucleic Acids Res 2015. 2015;43(Database issue):D1079-85.
13. Pique-Regi R, Monso-Varona J, Ortega A, Seeger RC, Triche TJ, Asgharzadeh S. Sparse representation and Bayesian detection of genome copy number alterations from microarray data. Bioinformatics. 2008;24:309-18.
14. Chiu CG, Nakamura Y, Chong KK, Huang SK, Kawas NP, Triche T, et al. Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem. 2014;60:873-85.
15. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29:308-11.
16. Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJ, Guchelaar HJ. UGT1A1 28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer. 2008;99:275-82.
17. Gil J, Sasiadek MM. Gilbert syndrome: the UGT1A1 28 promoter polymorphism as a biomarker of multifactorial diseases and drug metabolism. Biomark Med. 2012;6:223-30.
18. Zintzaras E, Ziogas DC, Kitsios GD, Papathanasiou AA, Lau J, Raman G. MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta analysis. Pharmacogenomics. 2009;10:1285-94.
19. Xie Q, Ratnasinghe LD, Hong H, Perkins R, Tang ZZ, Hu N, et al. Decision forest analysis of 61 single nucleotide polymorphisms in a case-control study of esophageal cancer. BMC Bioinform. 2005;6 Suppl 2:S4.
20. Martinez VD, Vucic EA, Thu KL, Pikor LA, Hubaux R, Lam WL. Unique pattern of component gene disruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in serous ovarian cancer. BioMed Res Int. 2014;2014:159459.
21. Chen CP, Fushing H, Atwill R, Koehl P. biDCG: a new method for discovering global features of DNA microarray data via an iterative re-clustering procedure. PLoS One. 2014;9:e102445.
22. Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994;3:67-71.
23. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014, 6: 224ra
24. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985-90.
25. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548-54.
26. Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016;7:48832-41.
27. Alahari SV, Eastlack SC, Alahari SK. Role of long noncoding RNAs in neoplasia: special emphasis on prostate cancer. Int Rev Cell Mol Biol. 2016;324:229-54.
28. Wu W, Sun M, Zou GM, Chen J. MicroRNA and cancer: current status and prospective. Int J Cancer. 2007;120:953-60.
29. Wang Y, Stricker HM, Gou D, Liu L. MicroRNA: past and present. Front Biosci. 2007;12:2316-29.
30. Chen PY, Meister G. MicroRNA-guided posttranscriptional gene regulation. Biol Chem. 2005;386:1205-18.
31. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development. 2005;132:4653-62.
32. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res. 2005;65:3509-12.
33. Lehmann U. Aberrant DNA methylation of microRNA genes in human breast cancer a critical appraisal. Cell Tissue Res. 2014;356:657-64.
34. Xiao YF, Yong X, Fan YH, Lü MH, Yang SM, Hu CJ. MicroRNA detection in feces, sputum, pleural effusion and urine: novel tools for cancer screening (review). Oncol Rep. 2013;30:535-44.
35. de Planell-Saguer M, Rodicio MC. Analytical aspects of microRNA in diagnostics: a review. Anal Chimica Acta. 2011;699:134-52.
36. Andorfer CA, Necela BM, Thompson EA, Perez EA. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med. 2011;17:313-9.
37. Zoon CK, Starker EQ, Wilson AM, Emmert-Buck MR, Libutti SK, Tangrea MA. Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert Rev Mol Diagn. 2009;9:455-67.
38. Deng S, Calin GA, Croce CM, Coukos G, Zhang L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle. 2008;7:2643-6.
39. Zhang L, Yang N, Coukos G. MicroRNA in human cancer: one step forward in diagnosis and treatment. Adv Exp Med Biol. 2008;622:69-78.
40. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101:2087-92.
41. Wang J, Zhang KY, Liu SM, Sen S. Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules. 2014;19:1912-38.
42. Farina NH, Wood ME, Perrapato SD, Francklyn CS, Stein GS, Stein JL, et al. Standardizing analysis of circulating microRNA: clinical and biological relevance. J Cel Biochem. 2014;115:805-11.
43. Schwarzenbach H. Circulating nucleic acids as biomarkers in breast cancer. Breast Cancer Res. 2013;15:211.
44. Ma R, Jiang T, Kang X. Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res. 2012;31:38.
45. Yu DC, Li QG, Ding XW, Ding YT. Circulating microRNAs: potential biomarkers for cancer. Int J Mol Sci. 2011;12:2055-63.
46. Mostert B, Sieuwerts AM, Martens JW, Sleijfer S. Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev Mol Diagn. 2011;11:259-75.
47. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 2010;15:673-82.
48. Vlassov VV, Laktionov PP, Rykova EY. Circulating nucleic acids as a potential source for cancer biomarkers. Cur Mol Med. 2010;10:142-65.
49. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251:499-505.
50. Zhu W, Qin W, Atasoy U, Sauter ER. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes. 2009;2:89.
51. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513-8.
52. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One. 2010;5:e13735.
53. Noren Hooten N, Fitzpatrick M, Wood 3rd WH, De S, Ejiogu N, Zhang Y, et al. Age-related changes in microRNA levels in serum. Aging (Albany NY). 2013;5:725-40.
54. Olivieri F, Rippo MR, Procopio AD, Fazioli F. Circulating inflamma-miRs in aging and age-related diseases. Front Genet. 2013;4:121.
55. Mishra PJ. MicroRNA polymorphisms: a giant leap towards personalized medicine. Per Med. 2009;6:119-25.
56. Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One. 2012;7:e35661.
57. Mishra PJ. Non-coding RNAs as clinical biomarkers for cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2014;14:917-9.
58. Mishra PJ. MicroRNAs as promising biomarkers in cancer diagnostics. Biomark Res. 2014;2:19.
59. Houseley J, Rubbi L, Grunstein M, Tollervey D, Vogelauer M. A ncRNA modulates histone modification and mRNA induction in the yeast GAL gene cluster. Mol Cell. 2008;32:685-95.
60. Pauli A, Valen E, Lin MF, Garber M, Vastenhouw NL, Levin JZ, et al. Systematic identification of long noncoding RNAs expressed during zebrafish embryogenesis. Genomes Res. 2012;22:577-91.
61. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629-41.
62. Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B. Tumour-suppressor activity of H19 RNA. Nature. 1993;365:764-7.
63. Shen J, Hu Q, Schrauder M, Yan L, Wang D, Medico L, et al. Circulating miR-148b and miR-133a as biomarkers for breast cancer detection. Oncotarget. 2014;5:5284-94.
64. Jungblut PR, Holzhütter HG, Apweiler R, Schlüter H. The speciation of the proteome. Chem Cent J. 2008;2:16.
65. Zhan X, Giorgianni F, Desiderio DM. Proteomics analysis of growth hormone isoform in the human pituitary. Proteomics. 2005;5:1228-41.
66. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem. 2003;72:291-336.
67. Kohler M, Thomas A, Pushel K, Schanzern W, Thevis M. Identification of human pituitary growth hormone variants by mass spectrometry. J Proteome Res. 2008;8:1071-6.
68. Okkels LM, Müller EC, Schmid M, Rosenkrands I, Kaufmann SH, Andersen P, et al. CFP10 discriminates between nonacetylated and acetylated ESAT-6 of Mycobacterium tuberculosis by differential interaction. Proteomics. 2004;4:2954-60.
69. Schlüter H, Apweiler R, Holzhütter HG, Jungblut PR. Finding one's way in proteomics: a protein species nomenclature. Chem Cent J. 2009;3:11.
70. Doetsch F. The glial identity of neural stem cells. Nat Neurosci. 2003;11:1127-34.
71. Li Z, Lu H, Yang J, Zeng X, Zhao L, Li H, et al. Analysis of the raw serum peptidomic pattern in glioma patients. Clin Chim Acta. 2013;425:221-6.
72. Kaddi CD, Parry RM, Wang MD. Multivariate hypergeometric similarity measure. IEEE/ACM Trans Comput Biol Bioinform. 2013;10:1505-16.
73. Veselkov KA, Mirnezami R, Strittmatter N, Kinross J, Speller A, Abramov T, et al. Chemo-informatic strategy for imaging mass spectrometry-based hyperspectral profiling of lipid signatures in colorectal cancer. Proc Natl Acad Sci U S A. 2014;111:1216-21.
74. Lee JH, Kim KH, Park JW, Chang HJ, Kim BC, Kim SY, et al. Low-mass-ion discriminant equation: a new concept for colorectal cancer screening. Int J Cancer. 2014;134:1844-53.
75. Lin XL, Yang SY, Du J, Tian YX, Bu LN, Huo SF, et al. Detection of lung adenocarcinoma using magnetic beads based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry serum protein profiling. Chin Med J (Engl). 2010;123:34-9.
76. Xu ZQ, Broza YY, Ionsecu R, Tisch U, Ding L, Liu H, et al. A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions. Br J Cancer. 2013;108:941-50.
77. Van Berkel JJ, Dallinga JW, Möller GM, Godschalk RW, Moonen E, Wouters EF, et al. Development of accurate classification method based on the analysis of volatile organic compounds from human exhaled air. J Chromatogr B Analyt Technol Biomed Life Sci. 861: 101-107.
78. van de Kant KD, van der Sande LJ, Jöbsis Q, van Schayck OC, Dompeling E. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review. Respir Res. 2012;13:117.
79. Horváth I, Lázár Z, Gyulai N, Kollai M, Losonczy G. Exhaled biomarkers in lung cancer. Eur Respir J. 2009;34:261-75.
80. Hazelbag S, Fleuren GJ, Baelde JJ, Schuuring E, Kenter GG, Gorter A. Cytokine profile of cervical cancer cells. Gynecol Oncol. 2001;83:235-43.
81. Yamamoto T, Kimura T, Ueta E, Tatemoto Y, Osaki T. Characteristic cytokine generation patterns in cancer cells and infiltrating lymphocytes in oral squamous cell carcinomas and the influence of chemoradiation combined with immunotherapy on these patterns. Oncology. 2003;64:407-15.
82. Gardner JW, Bartlett PN. Applications and advances in electronic-nose technologies. Sensors (Basel). 2009;9:5099-148.
83. Mazzone PJ, Wang XF, Xu Y, Mekhail T, Beukemann MC, Na J, et al. Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer. J Thorac Oncol. 2012;7:137-42.
84. Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, et al. Radiomics: the process and the challenges. Magn Reson Imaging. 2012;30:1234-48.
85. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441-6.
86. Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.
87. Zanin M, Menasalvas E, Boccaletti S, Sousa P. Feature selection in the reconstruction of complex network representations of spectral data. PLoS One. 2013;8:e72045.
88. Amarasinghe KC, Li J, Hunter SM, Ryland GL, Cowin PA, Campbell IG, et al. Inferring copy number and genotype in tumour exome data. BMC Genomics. 2014;15:732.